Gertrude B. Elion, a chemist working in the research laboratories of Burroughs Wellcome, revolutionized childhood cancer ...

Veteran immunologist and former Pfizer R&D leader joins Circurna to advance its circular RNA therapeutic platform ...

The technology, called the Viral-Engineered RNA-based Activation System (VERAS), hijacks the virus's own replication ...

Aurora Therapeutics, cofounded by Nobel Prize–winning scientist Jennifer Doudna, plans to use gene editing and a new FDA ...

Codexis Inc. and Axolabs have entered into an agreement under which Axolabs will evaluate Codexis’ ECO Synthesis ...

Researchers from Radboud university medical center and University of Basel have discovered new genetic causes of inherited ...

The companies will leverage Bayer's expertise in developing medicines for heart conditions and Soufflé's siRNA delivery technologies to advance the treatment.

Although the year brought a steady stream of new treatments, tests, and cutting-edge science, experts worry about how ...

Aperture Therapeutics is advancing APRTX-003, an RNA-based antisense therapy targeting MMP9, as a potential ALS treatment.

Access the Akari CEO Corner hereTAMPA, Fla. and LONDON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: ...

Product Performance – potency and dosing: Cryogenic transmission electron microscopy (Cryo-TEM) revealed more uniform, solid-core particles. Increased lipid and RNA concentrations can enhance in vivo ...

Retinitis pigmentosa (RP) is a genetic eye disorder affecting around one in 5,000 people worldwide. It typically begins with ...